Equibles does not estimate personal net worth.
Get an email with a short summary when Rani Therapeutics Holdings, Inc. publishes a filing, an earnings call transcript or a press release.
Get RANI alertsTalat Imran is recorded as CEO and Board Member at Rani Therapeutics Holdings, Inc. (RANI). The newest filing on record that lists Talat Imran as CEO and Board Member at Rani Therapeutics Holdings, Inc. (RANI) is dated April 16, 2026. The proxy statement of Rani Therapeutics Holdings, Inc. reports total compensation of $1,052,101 for Talat Imran in fiscal 2025, including a base salary of $198,325. Disclosed compensation is on record for 5 fiscal years. Talat Imran has spoken on 4 earnings calls and 2 other investor events across 1 company, most recently for Rani Therapeutics Holdings, Inc. on October 20, 2026. Rani Therapeutics Holdings, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Rani Therapeutics Holdings, Inc. includes Lisa Rometty (CEO), Mir Imran (Chairman), Nicholas M. Maestas (CFO) and 7 others.
“Well, he had spicy Indian food one night, and he had an upset stomach, and he'd been working on this for about a year and a half, but it had springs and levers, and it was really a complicated mechanical device. and when he dropped the Alka-Seltzer in water to calm his stomach, he said, okay, this is going to be it.”
“First off, Ed, thank you to you and to Canaccord for allowing us the opportunity here to have this conversation. And as you said, this is Nick's not only first interaction with you, but his first conference altogether, so make sure to ask him some tough questions.”
“Good afternoon, everyone, and thank you for joining our earnings call for the fourth quarter and full year of 2025. I'm pleased to share the highlights of what we believe was a transformational year for Rani Therapeutics.”
“I'm delighted to share the highlights of Rani Therapeutics' strong performance in 2023, during which the company achieved numerous milestones in the development of its pipeline programs and high-capacity oral delivery device.”
“Good afternoon everyone and thank you for joining our fourth quarter and full year 2022 financial results conference call.”
Start not stated–present
Last confirmed April 16, 2026
Start not stated–present
Last confirmed April 16, 2026
Biotechnology · Healthcare
CEO, Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Rani Therapeutics Holdings, Inc. (RANI) | Chief Executive Officer | $198,325 | $1,052,101 |
| 2024 | Rani Therapeutics Holdings, Inc. (RANI) | Chief Executive Officer | $105,818 | $3,042,245 |
| 2023 | Rani Therapeutics Holdings, Inc. (RANI) | Chief Executive Officer | $450,000 | $5,266,893 |
| 2022 | Rani Therapeutics Holdings, Inc. (RANI) | Chief Executive Officer | $515,000 | $4,311,190 |
| 2021 | Rani Therapeutics Holdings, Inc. (RANI) | Chief Executive Officer | $408,333 | $11,782,823 |
